Afimmune Ltd. to Participate at ACCESS CHINA Biotech Forum

By Yafo Life Sciences

December 26th, 2021 (Shanghai) — We are glad to announce that Moayed Hamza, the Senior Medical Director of Afimmune Ltd., has been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.

If you are interested in listening to the live event, please register at https://biotochina.org/register/

About Afimmune Ltd.

Afimmune, headquartered in Dublin, Ireland, is a clinical stage drug discovery and development company focused on the development of biologically active polyunsaturated lipids for the treatment of cardiometabolic diseases.
Afimmune has assets in various stages of clinical and preclinical development.

Afimmune’s lead compound is the active pharmaceutical substance Epeleuton, a synthetic derivative of the endogenous 15-HEPE (15-Hydroxy-Eicosapentaenoic Acid). 

About the speaker

Dr. Moayed Hamza is a physician with broad clinical and translational research and therapeutic experience. Dr Hamza contributes to all aspects of clinical strategy, research and development. He leads the design and implementation of clinical trials. Prior to joining Afimmune, Dr Hamza conceived and led several large health system improvement initiatives.


ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/

Contact US

Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum

For more information, please contact:

Wendi Xiang